Altamira Therapeutics Ltd. announced that its associate company, Altamira Medica, has obtained certification for its Bentrio nasal spray under the European Union's Medical Device Regulation (MDR). This certification confirms Bentrio's conformity with the EU's new, more stringent requirements for medical devices, enabling its commercialization across EU member states and facilitating regulatory approval in other countries. The MDR certification follows significant investment and clinical trials by Medica and marks a key milestone in the international expansion of Bentrio. There is no indication that funding or grant support was provided by organizations other than Altamira or its associate company.